Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEACON trial in relapsed or refractory neuroblastoma
NL-OMON50504Phase 2Recruiting
- Sponsor
- University of Birmingham
- Start
- Oct 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bevacizumab, temozolomide, irinotecan, topotecan and Dinutuximab beta in neuroblastoma (8 arms), sponsored by University of Birmingham. Primary endpoint: Best response. Started Oct 2015; status: recruiting.
02
Drugs
bevacizumabtemozolomideirinotecantopotecanDinutuximab beta
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NL-OMON50504.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50504.